Trials / Completed
CompletedNCT00002046
A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Glaxo Wellcome · Industry
- Sex
- All
- Age
- 13 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the pharmacokinetics of Retrovir (AZT) administered orally as 1 of 3 doses in the treatment of patients with severe clinical and laboratory manifestations of HIV infection. To compare the safety and tolerance of AZT administered 2, 3, and 6 x daily to these patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zidovudine |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00002046. Inclusion in this directory is not an endorsement.